Carvolol

Carvolol

carvedilol

Manufacturer:

GPO

Distributor:

GPO

Marketer:

GPO
Concise Prescribing Info
Contents
Carvedilol
Indications/Uses
Management of essential HTN as monotherapy or in combination w/ other antihypertensives eg, Ca channel blockers & diuretics. CHD. Patients w/ stable & symptomatic, mild, moderate & severe chronic heart failure of ischemic or non-ischemic etiology in combination w/ standard therapy (including ACE inhibitors & diuretics w/ or w/o digitalis).
Dosage/Direction for Use
Adult HTN Initially 12.5 mg once daily for the 1st 2 days. Recommended dose: 25 mg once daily. Dose titration: If necessary, dose may be increased at intervals of at least 2 wk to recommend max daily dose of 50 mg once or twice daily. CHD Initially 12.5 mg bid for the 1st 2 days. Recommended dose: 25 mg bid. Dosage titration: If necessary, the dose may be increased at intervals of at least 2 wk up to recommended max daily dose of 100 mg bid. CHF 3.125 mg bid for 2 wk. Dosage titration: If initial dose is tolerated, dose may be increased at intervals of not <2 wk, to 6.25 mg, 12.5 mg & 25 mg bid. Recommended max dose: Severe chronic heart failure 25 mg bid. Patients w/ mild to moderate chronic heart failure weighing >85 kg 50 mg bid, <85 kg 25 mg bid.
Administration
Should be taken with food.
Contraindications
Hypersensitivity. Decompensated cardiac failure requiring IV inotropic therapy. Bronchial asthma or related bronchospastic conditions, 2nd or 3rd degree AV block, sick sinus syndrome, severe bradycardia (except in patients w/ a functioning artificial pacemaker), cardiogenic shock, severe hepatic impairment.
Special Precautions
Do not w/draw abruptly especially in patients w/ CAD & gradually taper. History of severe anaphylaxis. Closely monitor patients during initial treatment & increase of dosage for symptomatic hypotension w/ or w/o syncope. Bradycardia. Initiate treatment cautiously & monitor for possible deterioration in status (eg, symptoms of heart failure) in patients w/ heart failure & risk factors including ischemic heart disease, diffuse vascular disease, underlying renal dysfunction &/or systolic BP <100 mmHg. Temporary reduce dose or discontinue treatment if worsening heart failure or fluid retention occurs. Patients w/ Prinzmetal variant angina, bronchospastic disease, DM, peripheral vascular disease. May potentiate hypoglycemia &/or mask sign & symptoms of DM. Monitor for progression of arterial obstruction. Do not routinely w/draw prior to major surgery. May mask signs of hyperthyroidism (eg, tachycardia). Carefully manage & monitor patients if hyperthyroidism is suspected. Initiate α-blockade prior to treatment in patients w/ pheochromocytoma. Floppy iris syndrome. Myasthenia gravis. Psoriasis. Mild to moderate hepatic impairment. Avoid driving or other hazardous task during initiation of therapy. Pregnancy & lactation.
Adverse Reactions
Dizziness, headache, fatigue, asthenia, arthralgia, hypotension, bradycardia, generalized edema, diarrhea, nausea, vomiting, hyperglycemia, wt gain, increased BUN, increased non-protein nitrogen, increased cough & abnormal vision. Anemia, dyspnea & pulmonary edema.
Drug Interactions
Potential pharmacokinetic interaction w/ drugs affecting hepatic microsomal enzymes potent inhibitors of CYP2D6 eg, fluoxetine, paroxetine, propafenone, quinidine. May increase hypoglycemic effect of antidiabetics (oral & parenteral insulin). Possible conduction disturbance w/ Ca channel blockers. May increase risk of bradycardia w/ cardiac glycosides (digoxin). Potential additive effects w/ catecholamine-depleting agents eg, reserpine, MAOIs; clonidine. May decrease metabolism & increase AUC w/ cimetidine. May increase cyclosporine conc. May increase plasma conc w/ fluoxetine, paroxetine, propafenone & quinidine. Increased risk of hypotension & heart failure w/ myocardial depressant general anesth eg, ether cyclopropane, trichloroethylene. Decreased peak plasma conc & AUC w/ rifampin.
MIMS Class
Beta-Blockers
ATC Classification
C07AG02 - carvedilol ; Belongs to the class of alpha and beta blocking agents. Used in the treatment of cardiovascular diseases.
Presentation/Packing
Form
Carvolol tab 12.5 mg
Packing/Price
10 × 10's
Form
Carvolol tab 6.25 mg
Packing/Price
10 × 10's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in